PA
SLNO

PharVision Advisers’s Soleno Therapeutics SLNO Stock Holding History

PharVision Advisers’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,257
Closed -$288K – 977
2025
Q3 		$288K Buy
+4,257
New +$316K 0.16% 252

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PharVision Advisers's SLNO Position: Q4 2025 in Review

PharVision Advisers sold out of Soleno Therapeutics (SLNO) in Q4 2025, closing a stake of 4,257 shares — an estimated $288K sold.

PharVision Advisers first reported a position in SLNO in Q3 2025 and held it in 1 quarter. The position peaked at $288K in Q3 2025. 248 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

  • PharVision Advisers reported no remaining Soleno Therapeutics position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 4,257 Soleno Therapeutics shares in Q4 2025, an estimated $288K.
  • PharVision Advisers first reported a position in Soleno Therapeutics in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Soleno Therapeutics position peaked at $288K in Q3 2025.
  • 248 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.